GlycoEra AG appoints Tanmoy Ganguly as Chief Scientific Officer

GlycoEra AG appoints Tanmoy Ganguly as Chief Scientific Officer

Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics

  • By IPP Bureau | June 17, 2022

GlycoEra announced the appointment of Tanmoy Ganguly, Ph.D., as Chief Scientific Officer.

Dr. Ganguly brings nearly 25 years of experience in biopharmaceutical research and development across a variety of therapeutic areas including autoimmune diseases, inflammation, and oncology, among others. He will lead GlycoEra's efforts to develop novel therapeutics targeting degradation of circulating and membrane proteins that cause disease, using the company's proprietary CustomGlycan platform.

"CustomGlycan enables custom design and development of unique and homogeneous glycans on proteins," said Dr. Ganguly. "I am eager to assume scientific leadership of the company and to partner with an impressive group of proven drug developers, during this pivotal period of growth, as we advance a range of assets toward clinical studies for the ultimate benefit of patients."

Dr. Ganguly brings deep experience leading R&D teams across multiple functional areas, with a proven track record in drug development and in translating platform programs into clinical candidates. He joins GlycoEra from Evelo Biosciences, where he served as Vice President, leading pharmacology, research analytics and bioinformatics. In his work at Evelo on its SINTAX platform, Dr. Ganguly advanced the first extracellular nanoparticle product – EDP2939 - towards clinical development. Prior to Evelo, Dr. Ganguly spent more than 11 years at Momenta Pharmaceuticals, where he led a team of scientists focused on the discovery and development of autoimmune, inflammation, and oncology product candidates. Before joining Momenta, Dr. Ganguly held a variety of research positions at BD Biosciences, UCB Pharma, Millennium Pharmaceuticals, and Helios Pharmaceuticals.

"The breadth and depth of Dr. Ganguly's expertise in lead generation, optimization, pharmacology, and translational research will serve GlycoEra well as we build the next stage of the company," said Ganesh V. Kaundinya, Ph.D., President and Chief Executive Officer of GlycoEra. "We continue to build the leadership infrastructure as a critical component of the organization to cultivate a high-value pipeline of medicines in the protein degradation space." 

GlycoEra announced the appointment of Dr. Kaundinya as President and CEO in May 2022. The addition of Dr. Kaundinya and Dr. Ganguly strengthens a leadership team comprised of seasoned biotechnology executives, including Amir Faridmoayer, Ph.D., Chief Technology Officer, and Dominique Sirena, Ph.D., Chief Manufacturing Officer.

Upcoming E-conference

Other Related stories